[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematopoetic-stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematopoetic-stem-cell-transplantation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,63,104,135,160,190,221],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":35,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100565518","early-phase-1-exercise-as-an-immune-adjuvant-for-allogeneic-cell-therapies-100565518",false,"NCT06643221","Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","Exercise-induced Adrenergic Receptor Signaling as an Immune Adjuvant for Allogeneic Cell Therapies","Allo-X","Procedures are in place for protecting against or minimizing the risks to the healthy volunteers recruited for this study. Physical risk to volunteers and matched related donors will be protected through health screening to determine study eligibility, and medical monitoring with an established test termination criterion during the exercise and isoproterenol infusion trials.\n\nTo protect against the remote risk of an adverse cardiac event occurring during exercise and isoproterenol infusion, the study will only enroll volunteers who are considered \"low risk\" for maximal stress testing in accordance with the guidelines published by the American College of Sports Medicine (ACSM) and American Heart Association (AHA). Individuals who are considered \"low risk\" are men and women who are asymptomatic and have no more than one risk factor for cardiovascular disease (CVD). The risks to subjects are therefore extremely low. All infusions will take place in the Clinical and Translational Sciences Research Center (CATS) Infusion Suite, which is a designated University of Arizona campus facility for infusion trials and equipped with appropriate medical personnel and monitoring equipment (i.e. ECG). The graded exercise tests and isoproterenol infusions procedures will be performed under the direction of a licensed and board-certified cardiologist\n\nInclusion Criteria:\n\nParticipants must:\n\n* Be between 21 and 55 years of age.\n* Be classified as 'low-risk' for graded exercise\u002Fstress testing according to ACSM-AHA criteria.\n* Have no contraindications for the use of isoproterenol, carvedilol, bisoprolol, nadolol, or roflumilast as per FDA guidelines.\n\nExclusion Criteria:\n\nParticipants will be excluded if they:\n\n* Currently use tobacco products or have quit within the last 6 months.\n* Have a body mass index (BMI) greater than 34 kg\u002Fm² or waist circumference exceeding 102 cm for men and 88 cm for women.\n* Use any medications known to affect the immune system or regularly take ibuprofen\u002Faspirin, antidepressants, or medications that alter blood pressure or cardiovascular function.\n* Use of hormone replacement therapy.\n* Are pregnant or breastfeeding.\n* Have chronic or debilitating arthritis or have been bedridden in the past three months.\n* Experienced a common illness (e.g., colds) within the past 6 weeks.\n* Have central or peripheral nervous disorders, a history of stroke, or major affective disorder.\n* Are infected with HIV or hepatitis or have any autoimmune disease.\n* Have known cardiovascular disease or contraindications for the use of isoproterenol, carvedilol, bisoprolol, nadolol, or roflumilast.\n* Use any prescription medications or have an allergy to beta-blockers.\n* Have a resting heart rate of less than 50 beats per minute.\n* Suffer from asthma, emphysema, bronchitis, kidney disease, pheochromocytoma, diabetes, overactive thyroid, or a history of severe anaphylactic reactions.\n* Are scheduled for surgery.\n\nAdditionally, participants who meet the inclusion criteria but present with more than one of the following cardiovascular disease (CVD) risk factors will be excluded unless cleared by a cardiologist:\n\n* Family History: Myocardial infarction, coronary revascularization, or sudden death before 55 years of age in a father or male first-degree relative, or before 65 years of age in a mother or female first-degree relative.\n* Hypertension: Systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg.\n* Dyslipidemia: Total serum cholesterol exceeding 200 mg\u002Fdl.\n* Pre-diabetes: Fasting blood glucose levels between 100 mg\u002Fdl and 126 mg\u002Fdl.",true,"ALL","21 Years","55 Years",{"count":22,"type":23},200,"ESTIMATED","INTERVENTIONAL",[26],"EARLY_PHASE1","This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a cancer patient, usually to help prevent or treat cancer relapse after a stem cell transplant. These donor cells can either be directly infused into the patient or grown in a lab to create more specialized immune cells that target and kill cancer. While this therapy has been helpful for many patients, there is a need to make it more effective for a larger group and reduce side effects like graft-versus-host disease (GvHD), where the donor's immune cells attack the patient's healthy tissue.\n\nThis Early Phase 1 trial will test whether exercise can help produce better immune cells from donors. The investigators will recruit healthy participants for three study groups:\n\n1. Exercise Group: Participants will complete a 20-minute cycling exercise session. The investigators will collect blood samples before, during, and after exercise to study the number and quality of immune cells. The investigators will also use the collected cells to create immune therapies and test their ability to kill cancer cells in the lab and control cancer growth in mice.\n2. Exercise and Beta Blocker Group: In this group, participants will complete up to five cycling sessions, with at least a week between each session. Before each session, participants will take either a placebo or a drug (beta blocker) that blocks stress hormones like adrenaline. The investigators will collect blood samples before and during exercise to see how blocking these hormones changes the effect of exercise on immune cells.\n3. Isoproterenol Group: Participants in this group will receive a 20-minute infusion of isoproterenol, a drug that mimics the effects of adrenaline. The investigators will collect blood samples before, during, and after the infusion to see if the drug causes similar immune changes to those caused by exercise.\n\nParticipants can join one, two, or all three groups. This research will help understand whether exercise can improve immune cell therapies for treating blood cancer and reduce the risk of GvHD, making these treatments safer and more effective.",[29,30,31,32,33,34],"Leukemia","Hematopoetic Stem Cell Transplantation","Donor Lymphocyte Infusion","CAR T-Cell Therapy","Lymphoma","Cell Therapy",[36,37,38,39,40,41,42,43,44,45,46,47,48,49],"exercise","cell therapy","beta-blockers","immune function","phosphodiesterase inhibitor","CAR T-cells","NK-cells","cytokine-induced killer cells","cytokine-induced memory-like NK-cells","monoclonal antibodies","leukemia","lymphoma","donor lymphocyte infusion","gamma-delta T-cells","RECRUITING","2026-06-03",{"date":53,"type":54},"2026-06-05","ACTUAL",{"date":56,"type":54},"2018-01-24",{"date":58,"type":23},"2031-05-31",{"name":60,"class":61},"University of Arizona","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":18,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":24,"phases":75,"briefSummary":77,"conditions":78,"keywords":88,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100632820","phase-1-phase-i-clinical-trial-of-thinkk-adoptive-immunotherapy-after-allogeneic-hematopoietic-transplantation-in-children-with-leukemia-or-neuroblastoma-100632820","NCT07518654","Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma","Phase I Clinical Trial of Therapeutic Inducers of Natural Killer Killing (ThINKK) Adoptive Immunotherapy: Feasibility, Safety and Pharmacodynamics in Children Undergoing Allogenic Hematopoietic Transplantation for Leukemia or Neuroblastoma","ThINKK-01","Inclusion Criteria:\n\n1. Between 2 and less than 13 years old at time of informed consent form signature.\n2. Diagnosis of acute leukemia or neuroblastoma.\n3. Allogenic hematopoietic stem cell transplantation 30 to 90 days prior to eligibility confirmation.\n4. Blood NK cell counts ≥ 100 x 10E+6 cells\u002FL at least once before eligibility confirmation.\n5. Life expectancy of ≥ 3 months per investigator's judgment at time of eligibility confirmation.\n6. Patient or legally acceptable representative has provided informed consent based on local regulations and\u002For guidelines prior to any study-specific activities\u002Fprocedures being initiated.\n\nExclusion Criteria:\n\n1. Current grade 3 or 4 acute GvHD (per MAGIC criteria).\n2. Relapse of primary malignancy, or any other active malignancy.\n\n   1. For leukemia, defined as either morphological relapse or Minimal Residual Disease (MRD) ≥0.01% as measured by flow cytometry. MRD detected by polymerase chain reaction (PCR) does not constitute an exclusion criterion.\n   2. For neuroblastoma, defined as a progressive disease.\n3. Ongoing therapy with systemic corticosteroids (equivalent to a prednisone dose \\>0.5 mg\u002Fkg\u002Fday). Patients actively undergoing corticosteroid tapering during Screening may be enrolled once they have reached a prednisone-equivalent dose ≤ 0.5 mg\u002Fkg\u002Fday with Sponsor-Investigator approval, with the expectation that the taper will continue.\n4. Ongoing systemic therapy with cyclosporine.\n5. Administration or planned administration of any prohibited treatment listed in ad hoc section.\n6. Aspartate aminotransferase and alanine aminotransferase serum levels ≥5 times the upper limit of normal.\n7. Direct bilirubin serum levels ≥3 times the ULN (unless due to Gilbert syndrome).\n8. Baseline estimated glomerular filtration rate \\\u003C 50 mL\u002Fmin\u002F1.73 m2, as determined using the Bedside Schwartz equation for \\\u003C 18 years of age.\n9. Grade 4 diarrhea (ie, life-threatening consequences with urgent intervention indicated).\n10. O2 Sat saturation \\\u003C90% on room air by pulse oximetry.\n11. Uncontrolled life-threatening symptomatic infection(s).\n12. Blood pressure below the 5th percentile for age, sex, and height last 24 hours.\n13. Ongoing therapy with intravenous vasopressor agent.\n14. Any condition that, in the opinion of the Investigator, would compromise the safety of the patient, would prevent full participation in this study, or would interfere with the evaluation of any study endpoints.\n15. Pregnancy or breastfeeding or absence of highly effective methods of contraception for males and females of childbearing potential who engage in heterosexual intercourse","2 Years","12 Years",{"count":74,"type":23},12,[76],"PHASE1","A first-in-class adoptive immunotherapy we called ThINKK, for Therapeutic Inducers of Natural Killer (NK) cell Killing, have been designed for use after hematopoietic stem cell transplantation (HSCT), where the proper stimulation of graft-derived NK cells has been shown to prevent relapse.\n\nThINKK immunotherapy builds on our earlier research on NK cells and plasmacytoid dendritic cells (PDC) in cord blood and after HSCT. PDC are the sentinels of the immune system. Upon viral nucleic acids detection, PDC secrete a vast array of chemokines and cytokines that stimulate NK cells. PDC stimulation enhances NK cells killing of infected cells that express stress-induced molecules. Cancer cells also express stress-related molecules at their surface. However, NK cells do not receive PDC stimulation when fighting cancer. ThINKK therapy is designed to provide this necessary stimulation.",[79,80,81,82,83,84,85,86,30,87],"Leukaemia (Acute Lymphoblastic)","Leukaemia (Acute Myeloid)","Neuroblastoma","Neuroblastoma, Metastatic","Leukaemia, Lymphoblastic, Acute","Leukemia Acute Myeloid","Leukemia (Both ALL and AML)","Leukemia Acute Myeloid - AML","Hematopoetic Stem Cell Transplant",[89,90,91,92],"Thinkk","NK cells","pdc","immunotherapy","NOT_YET_RECRUITING","2026-04-02",{"date":96,"type":54},"2026-04-08",{"date":98,"type":23},"2026-05-01",{"date":100,"type":23},"2029-05-01",{"name":102,"class":61},"Michel Duval",2,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":18,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":24,"phases":116,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":62},"100632496","animation-based-education-to-reduce-child-and-parent-anxiety-during-pediatric-stem-cell-transplantation-cartoon-hsct-100632496","NCT07514442","Animation-Based Education to Reduce Child and Parent Anxiety During Pediatric Stem Cell Transplantation (Cartoon-HSCT)","The Effect of Animation-Based Education on Child and Parent Anxiety and Care Satisfaction During the Hematopoietic Stem Cell Transplantation Process: A Randomized Controlled Trial","Cartoon-HSCT","Inclusion Criteria:\n\nChildren:\n\nAged 4 to 10 years. Scheduled for hematopoietic stem cell transplantation. No previous history of hematopoietic stem cell transplantation. Ability to communicate verbally in Turkish. No diagnosed cognitive impairment. Provided age-appropriate verbal assent if aged 7 years or older. Written informed consent provided by a legal parent or guardian.\n\nParents:\n\nParent or legal guardian of a child aged 4 to 10 years scheduled for hematopoietic stem cell transplantation.\n\nRemaining with the child as the primary caregiver\u002Fcompanion throughout the HSCT hospitalization.\n\nAbility to communicate verbally in Turkish. Willingness to participate and provision of written informed consent.\n\nExclusion Criteria:\n\nChildren:\n\nNative language other than Turkish or significant difficulty communicating in Turkish.\n\nPrevious hematopoietic stem cell transplantation. Development of severe clinical complications before or during transplantation requires modification of the treatment protocol.\n\nTransfer to another clinic prior to transplantation. Significant emotional distress during the animation intervention, as assessed by the research team.\n\nParents:\n\nNative language other than Turkish or significant difficulty communicating in Turkish.\n\nChange in caregiver\u002Fcompanion role during the transplantation process.","4 Years","10 Years",{"count":115,"type":23},34,[117],"NA","The goal of this clinical trial is to evaluate the effect of animation-based education on state anxiety levels of children and parents and on parental satisfaction with health care during the pediatric hematopoietic stem cell transplantation (HSCT) process.\n\nThe main questions it aims to answer are:\n\nDoes animation-based education reduce children's state anxiety before HSCT compared to standard verbal education? Does animation-based education reduce parental state anxiety and increase parental satisfaction with the care process?\n\nResearchers will compare children and parents who receive animation-based education with those who receive routine verbal education to see if the animation-based intervention leads to lower anxiety scores and higher satisfaction levels.\n\nParticipants will:\n\nWatch a short age-appropriate animated video explaining the HSCT procedure in a positive and understandable way (intervention group), or receive standard verbal information (control group).\n\nComplete pre- and post-intervention questionnaires assessing child and parent state anxiety levels and parental satisfaction with care.\n\nThe study includes children aged 4-10 years who are hospitalized for hematopoietic stem cell transplantation and their accompanying parents.",[30],[121,122,123,124,125],"Child","Parents","Hematopoietic Stem Cell Transplantation","Anxiety","Personal Satisfaction","2026-04-01",{"date":128,"type":54},"2026-04-07",{"date":130,"type":23},"2026-04",{"date":132,"type":23},"2027-06",{"name":134,"class":61},"Hacettepe University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":18,"minAge":142,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":62},"100601182","psychosocial-and-behavioral-intervention-for-stem-cell-transplant-patients-and-their-family-caregivers-100601182","NCT07107165","Psychosocial and Behavioral Intervention for Stem Cell Transplant Patients and Their Family Caregivers","Adapting After Discharge From Allogeneic SCT: Partnering Together; Dyadic Intervention to Improve Patient-Family Caregiver Team-Based Management of the Medical Regimen After Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Patient undergoing a stem cell transplant at the University of Pittsburgh Hillman Cancer Center\n* 18 years or older\n* having a family caregiver age 18 years or older also willing to participate in the study\n* willing to accept randomization\n\nExclusion Criteria:\n\n* Prior history of stem cell transplant\n* Non-English speaking","18 Years",{"count":144,"type":23},208,[117],"Adherence to the medical regimen after stem cell transplant is challenging for both patients and their family caregivers. The investigators propose a randomized clinical trial testing two brief psychosocial interventions to determine if either improves patient and family caregiver psychosocial and health-related outcomes.",[148,87,30],"Stem Cell Transplant",[150,151],"stem cell transplant","hematopoietic stem cell transplant","2026-03-26",{"date":126,"type":54},{"date":155,"type":54},"2025-07-01",{"date":157,"type":23},"2027-07",{"name":159,"class":61},"University of Pittsburgh",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":18,"minAge":142,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":24,"phases":170,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100620837","phase-2-g-csf-combined-with-il-11-on-hematopoietic-reconstitution-after-autologous-hematopoietic-stem-cell-transplantation-100620837","NCT07362810","G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation","The Impact of G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Adults (≥18 years) with newly diagnosed multiple myeloma or lymphoma\n* Suitable candidates for autologous hematopoietic stem cell transplantation (auto-HSCT)\n* Zubrod (ECOG) performance status \\\u003C 4\n* Left ventricular ejection fraction (LVEF) \\> 40%\n* No uncontrolled arrhythmia or unstable cardiac disease\n* Corrected QT interval (QTc) \\\u003C 470 ms\n* No symptomatic pulmonary disease, with acceptable pulmonary function tests\n* Serum alanine aminotransferase (ALT) \\\u003C 4 × upper limit of normal (ULN)\n* Total bilirubin \\\u003C 2 × upper limit of normal (ULN)\n\nExclusion Criteria:\n\n* Intolerance to auto-HSCT\n* Prior exposure to other stem cell mobilizing agents\n* Pregnancy or lactation\n* Psychiatric disorders precluding participation\n* Positive serology for HIV (HIV-1\u002F2), hepatitis B, or hepatitis C","70 Years",{"count":169,"type":23},224,[171],"PHASE2","Autologous hematopoietic stem cell transplantation(auto-HSCT) plays an important role in treating hematologic malignancies. Mobilization and collection of peripheral blood stem\u002Fprogenitor cells is the key to successful autologous hematopoietic stem cell transplantation. Currently mobilization regimens are not enough in increasing the yield of megakaryocytic or erythroid stem\u002Fprogenitor cells, resulting in a delay of hematopoietic reconstitution of platelets and erythrocytes. IL-11 and G-CSF have a synergistic role in mobilizing peripheral blood stem cells towards megakaryocytic or erythroid stem\u002Fprogenitor cells in a preclinical study. Furthermore, a single-center, small cohort, prospective clinical study that has been completed in China(ChiCTR2500100054), which showed that after five days of mobilization, the combination of G-CSF and IL-11 significantly increased the number and proportion of functional megakaryocytic\u002Ferythroid progenitor cells in the peripheral blood mononuclear cells of patients, and also significantly shortened the time for platelet engraftment after transplantation, and also reduced the demand for red blood cell and platelet transfusions compared to G-CSF alone. A multi-center, prospective random clinical study is essential to compare the efficacy and safety of novel mobilization regimen with IL-11 plus G-CSF to G-CSF alone.",[174,30,175],"Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)","Hemato-oncologic Patients",[177,178,179],"IL-11","mobilization","hematopoetic stem cell transplantation","2026-01-22",{"date":182,"type":54},"2026-01-23",{"date":184,"type":23},"2026-01-01",{"date":186,"type":23},"2026-12-30",{"name":188,"class":61},"Fudan University",3,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":200,"phases":4,"briefSummary":201,"conditions":202,"keywords":206,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":216,"leadSponsor":218,"locationsCount":220},"100618215","critical-illness-after-hematopoietic-cell-transplantation-100618215","NCT07328724","Critical Illness After Hematopoietic Cell Transplantation","Critical Illness Among Recipients of Hematopoietic Cell Transplantation (CARE-HCT): a Prospective, Multicenter Observational Study in China","CARE-HCT","Inclusion Criteria:\n\n* Patients who underwent hematopoietic cell transplantation at any of the participating medical centers.\n* Patients who are admitted to ICU for the management of critical illness following hematopoietic cell transplantation.\n\nExclusion Criteria:\n\n* Admitted to ICU for a reason other than critical illness (e.g., routine postoperative monitoring) and discharged within 2 days of ICU admission.\n* Unavailable in-ICU clinical outcomes or absent key baseline characteristics.\n* Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.",{"count":199,"type":23},4000,"OBSERVATIONAL","This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation. Patients who are admitted to the intensive care unit after undergoing hematopoietic cell transplantation at the participating medical centers will be enrolled in this study. The clinical characteristics, laboratory profiles, managements, and clinical outcomes will be prospectively collected.",[203,204,30,205],"Critical Illness","Ventilated Patients","Transplant Complication",[207,208,209,210,211],"hematopoietic cell transplantation","critical illness","management","prognosis","transplant complication","2025-12-27",{"date":214,"type":54},"2026-01-09",{"date":184,"type":23},{"date":217,"type":23},"2036-12-31",{"name":219,"class":61},"Peking University People's Hospital",6,{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":18,"minAge":142,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":24,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":4},"100604118","virtual-reality-intervention-for-symptom-management-in-stem-cell-transplantation-100604118","NCT07145359","Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation","Development and Evaluation of A Virtual Reality Intervention for Symptoms Management During Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Able to speak and understand Turkish\n* Scheduled to undergo allogeneic hematopoietic stem cell transplantation (HSCT)\n* Receiving stem cell products collected from peripheral blood\n* Voluntarily agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Undergoing autologous hematopoietic stem cell transplantation\n* Receiving stem cell products collected from bone marrow\n* Diagnosed with medical or psychiatric comorbidities that could interfere with participation, as reported by the healthcare team\n* Presenting infection symptoms (e.g., respiratory, gastrointestinal) that may contaminate study equipment, as identified by the healthcare team\n* Having visual, auditory, verbal, or cognitive impairments that may prevent interaction with the VR equipment\n* Previously received any form of hematopoietic stem cell transplantation",{"count":229,"type":23},30,[117],"The goal of this clinical trial is to evaluate whether a virtual reality (VR) intervention based on the Symptom Management Model can reduce physical and psychosocial symptoms during hematopoietic stem cell transplantation (HSCT) in adult patients undergoing allogeneic transplantation.\n\nThe main questions it aims to answer are:\n\nDoes the VR intervention reduce distress levels during HSCT?\n\nDoes the VR intervention decrease state anxiety and symptom severity compared to standard care?\n\nDoes the VR intervention positively affect physiological outcomes and engraftment times?\n\nResearchers will compare a group receiving standard clinical care plus a VR nature-themed video during HSCT to a group receiving standard care only to see if the VR intervention improves symptom management outcomes.\n\nParticipants will:\n\nBe randomly assigned to either the intervention or control group.\n\nIn the intervention group:\n\nWatch a 15-minute nature-themed VR video during stem cell infusion using Meta Quest 3.\n\nThe video content will be specifically created by the research team based on the principles of Attention Restoration Theory (ART).\n\nIn both groups:\n\nComplete pre- and post-intervention assessments including:\n\nDistress Thermometer\n\nState-Trait Anxiety Inventory\n\nEdmonton Symptom Assessment Scale\n\nPhysiological measures (vital signs)\n\nEngraftment tracking\n\nSatisfaction and open-ended feedback forms",[233,30,234,235,236,237],"Cancer and \u002F or Hematological Malignancy","Nursing Interventions","Symptom Management","Virtual Reality","ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION","2025-08-21",{"date":240,"type":54},"2025-08-28",{"date":242,"type":23},"2025-09-10",{"date":244,"type":23},"2026-09-10",{"name":246,"class":61},"Halic University"]